Sharon Wilks

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2014 · 489 citations

Advanced Breast Cancer, Breast Oncology, Oncology +8

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

Fabrice André, Sara A. Hurvitz, Angelica Fasolo et al. · Journal of Clinical Oncology · 2016 · 165 citations

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

Hui Yu, Cory Batenchuk, A. Badzio et al. · Journal of Thoracic Oncology · 2016 · 134 citations · Full text

Oncology, Pd-l1 Expression, Medicine +10